Information describing alterations in vascular function during either acute or prolonged normobaric or hypobaric hypoxia is sparse and often confounded by pathology and methodological limitations.
Introduction
Ambient hypoxia associated with high altitude is a potent activator of the sympathetic nervous system (Saito et al., 1988; Marshall, 1994; Duplain et al., 1999; Xie et al., 2001; Hansen & Sander, 2003) , which causes vascular dysfunction (Hijmering et al., 2002) . Indeed, intermittent or sustained hypoxia in pathologies such as sleep apnoea, have been associated with vascular dysfunction (Lurie, 2011; Phillips et al., 2013) . However, information describing alterations in vascular function during either acute or prolonged exposure to high altitude is sparse and often confounded by pathology (i.e. acute / chronic mountain stickiness, metabolic syndrome) and methodological issues. Previously, acute exposure to high altitude (3,450 m and 4,770 m) has been reported to impair endothelial function (Rhodes et al., 2011) . However, these conclusions were based on measurements derived from finger photoplethysmography and derived estimates of changes in arterial stiffness and tone, rather than the more direct and widely adopted noninvasive measures of pulse-wave velocity (PWV; a measure of arterial stiffness (Laurent et al., 2006) ) and endothelium flow-mediated dilatation (FMD; as a measure of vascular function (Corretti et al., 2002; Green, 2005) ). Endothelial-dependent FMD was unchanged during acute exposure but impaired following the prolonged exposure (despite participation in an exercise intervention over this period). However, methodological issues existed which cloud interpretation of those data, including: lack of a control group; uncertain non standardisation of cuff placement during the FMD assessment, and lack of continuous monitoring of artery diameter and blood flow during reactive hyperaemia (Thijssen et al., 2011) . Specifically, the lack of continuous monitoring of artery diameter and blood flow can result in measurement error, and the true peak response may have been missed (Black et al., 2008) . Furthermore, 1700 m is a relatively weak hypoxic stimulus relative to altitudes that are readily accessed or lived in by many, thus the potential negative effect of highaltitude exposure on vascular function and structure in lowlanders, especially in a non-diseased population has not been adequately established.
Impairments in brachial vascular function and structure have been recently documented in native Andean highlanders, with chronic mountain sickness (Rimoldi et al., 2012; Bailey et al., 2013) .
Despite elevated levels of oxidative stress, endothelial-dependent FMD in the highlanders free from chronic mountain sickness was found to be comparable to healthy lowlanders at sea level (Rimoldi et al., 2012 ). Yet, healthy lowlanders exposed to acute normobaric hypoxia exhibited vascular dysfunction, based on indirect biomarkers of oxidative stress (Bailey et al., 2013) .
Whilst the research findings of Rimoldi et al. (2012) and Bailey et al. (2013) are relevant to chronic mountain sickness, vascular function in healthy lowlanders travelling from sea level to high altitude has not been comprehensively examined, nor compared with permanent highaltitude residents. The latter is of particular interest given that native highlanders have been reported to show earlier cardiovascular degeneration changes with ageing, in particular arterial wall stiffening (Otsuka et al., 2005) .
We therefore aimed to 1) Examine potential alterations in vascular function and structure in healthy lowlanders following initial ascent and ~2 weeks of acclimatisation to high altitude (5050 m), and 2) Examine the potential effect of chronic exposure to hypoxia on vascular function and structure in native Sherpa's (highlanders) born and permanently residing at high altitude. We hypothesised that: 1) Lowlanders' endothelial-dependent FMD and arterial stiffness would be impaired following acute exposure to high altitude, and further impairments would be evident following a more chronic stay at high altitude; 2) Measures of vascular function and structure in highlanders would be comparable to lowlanders at sea level; however, following ~2 weeks of high-altitude exposure, measures of vascular function and structure would be impaired in lowlanders compared to highlanders. To provide some mechanistic insight into potential alterations in vascular function, hypoxic-mediated alterations in systemic oxidative stress, nitrite (NO 2 ) and antioxidants were also quantified from plasma samples. It was anticipated that increased oxidative stress and concomitant reductions in NO 2 at high altitude would be related to impairments in vascular function.
In addition, based on the findings from this study (study 1) we conducted a follow-up study (study 2) to gain further insight on the mechanisms and time-course changes in the FMD response during acute hypoxic exposure. An increase in sympathetic outflow has previously been shown to attenuate FMD by ~57% (relative), yet this attenuation was completely abolished by alpha (α)-adrenergic blockade (Hijmering et al., 2002) . We reasoned that the FMD impairment seen with high altitude might also have been mediated via elevations in sympathetic nerve activity via an α-adrenergic mechanism; therefore, blocking the hypoxic-induced elevations in sympathetic nerve activity may potentially restore FMD. To address this possibility, we conducted a placebo-controlled experiment (study 2; n=11) in a normobaric hypoxic chamber (FIO 2 =~0.11; ~6 h) following selective α 1 -sympathetic receptor blockade (1 mg/20 kg body mass; prazosin). We hypothesised that: 1) FMD would be progressively impaired in normobaric hypoxia, and 2) α 1 -adrenergic blockade would partially normalize the hypoxic-induced reductions in FMD. Canada). Continuous beat-to-beat measures of arterial blood pressure (BP; finger photoplethysmography; Finapres Medical Systems, Biomedical Instruments, The Netherlands) and heart rate (HR, 3-lead ECG; ML132, ADInstruments, Colorado Springs CO, USA) were recorded. Manual sphygmomanometer BP recordings were obtained during supine rest to confirm the accuracy of the finger photoplethysmography measurements. All data were sampled continuously using an analogue-digital converter (PowerLab/4S ML750; ADInstruments) interfaced with a computer and displayed in real time during testing. Data were stored for subsequent off-line analysis using the commercially available software (Chart v7, ADInstruments). All tests were completed in the following order:
Arterial stiffness: Adhering to the international guidelines (Laurent et al., 2006) , hand heldtonometry (SPT-301 Millar Instruments, Houston, Texas) was employed to assess central (carotid-femoral PWV) and peripheral (carotid-radial PWV) arterial stiffness. Twenty reproducible carotid-femoral artery waveforms and 20 separate carotid-radial artery waveforms were recorded simultaneously using mechanotransducers, which were applied directly to the skin and over the area of greatest pulsation. The distance from the 4 th intercostal space in the midline of the sternum to the individual carotid, femoral and radial artery pulse sites were measured along the surface of the body using a measuring tape. This technique was used as it has been shown to have the best agreement with aortic PWV measured invasively using cardiac catheterization (Weber et al., 2009) . The foot to foot method was used to determine pulse transit time, using a bandpass filter (5-30 Hz) to identify the foot or "notch" of the carotid-femoral andradial waveform, and the difference in time from R interval to systolic upstroke at each location.
Pulse distance was determined by subtracting the distance from carotid measurement to the sternal notch from the distance from the sternal notch to the femoral and radial pulse site measurement. Pulse-wave velocity was then determined by dividing distance by pulse transit time. The day-to-day intra-observer coefficient variation (CV) for central and peripheral PWV (n=6) was 4.8% and 4.7%, respectively (Lewis et al., unpublished observations).
Local artery stiffness in the common carotid artery (CCA) was also assessed. Carotid ultrasound images and carotid BP were collected simultaneously over 20-30 cardiac cycles. Left CCA BP waveforms, a representative of carotid arterial pressure, were obtained using the hand-held tonometer positioned over the greatest pulsation. Right CCA ultrasound images were obtained ~1-2 cm proximal to the bifurcation of the external and internal carotid arteries using a 10-MHz multifrequency linear array probe, attached to a B-mode high-resolution ultrasound machine [Terason 3000TM, Teratech, Burlington, MA, USA] . Maximal and minimal lumen diameters were calculated using edge-detection software (described below). Ten carotid and brachial waveforms along with 10 complete cardiac cycles of carotid diameter change were averaged, and carotid arterial compliance, distensibility and ß-stiffness index were calculated (Tanaka et al., according to established methods (Pelletier et al., 2006) . The intra and inter-assay CV were both <5%.
Study 2 -Normobaric hypoxia and α 1 -adrenoreceptor blockade
Eleven healthy normotensive volunteers (7 males: 4 females) with a mean (± SD) age of 24 ± 3 years, body mass 75 ± 10 kg, height 174 ± 6 cm and body mass index 25 ± 3 kg/m 2 , participated in this randomized placebo-controlled experiment. Experimental sessions commenced between 08:00 and 09:00 hrs and measurements of FMD, SaO 2 and BP (as described above) were made in normoxia and during normobaric hypoxia (FIO 2 =0.11) at 60 min, 210 min and 330 min, and then 60 min after returning to normobaric normoxia (Figure 1 ). This level of hypoxia was chosen as it equivalent to an altitude of 5,000 m. Participants ingested the α 1 -adrenoreceptor blocker, prazosin (1 mg/20 kg body mass) or an identical placebo capsule 90 min before the last assessment in hypoxia. Prazosin has been shown to induce systemic peripheral arterial-dilation and venodilation via the removal of sympathetic nerve activity (Awan et al., 1977; Jauernig et al., 1978) . This clinically-acceptable dose of prazosin has previously been shown to have a functional block of ~80% and peak activity 90-to 180-min post-ingestion (Ogoh et al., 2008; Jones et al., 2011; Lewis et al., 2012 Lewis et al., , 2013 . Each experiment was separated by ≥ 7 days, and a small standardised snack and 250 mL of water were provided following each FMD assessment.
Data Analysis
Calculations: Baseline measures of BP and HR were averaged over 1 min following 15-min supine rest. Custom-designed edge-detection and wall-tracking software, which is largely independent of investigator bias, was utilised for the analysis of CCA and brachial diameter and brachial blood flow velocity [(Woodman et al., 2001; Black et al., 2008) Statistical analysis: All data were analysed using SPSS (version 21, IBM, Surrey, UK) and expressed as mean ± SD. Statistical significance was defined as P≤0.05 and distribution normality confirmed using repeated Shapiro-Wilk W tests. Study 1: Trial differences within lowlanders between sea-level, initial-high altitude and prolonged-high altitude were analysed using a one-way repeated measures ANOVA. Pearson's correlation analysis was used to examine the relationship between measures. Difference between highlanders and lowlanders at were explored using independent t-tests. Study 2: The time course changes of hypoxia in the placebo trial were examined using one-way repeated measures ANOVA, to establish the effect of the hypoxic stimulus on FMD. To examine the interaction between the time course change and experimental condition (placebo vs. α 1 -blockade) a two-way repeated measures ANOVA was used; to further exposure any significant interaction effect, paired t-tests were used to exposure the effect of the α 1 -blockade on the vascular changes with hypoxia.
Results

Study 1
Lowlanders at high altitude: Arterial oxygen saturation was markedly lower and HR was significantly higher following acute-high altitude (-18 ± 2% and +21 ± 4 beats•min -1 , respectively; P<0.001) and chronic prolonged-high altitude exposure (-16 ± 3% and +18 ± 4 beats•min -1 ; P<0.001; Table 1) (relative ~8%) following initial arrival to altitude and following ~2 weeks, respectively.
Compared with initial arrival to 5050 m, FMD shear rate area under the curve was lower following ~2 weeks at altitude (by 81,568 ± 3,856 AUC , P=0.03; Table 1 ), while no other differences were evident across the time spent at 5050 m (Table 1) . Compared to sea level, allometrically "corrected" FMD was also reduced by 1.2 ± 0% (relative ~15%) and 0.6 ± 0%
(relative ~8%) following acute and chronic high altitude exposures, respectively (P≤0.03; Table   1 ).
Markers of oxidative stress and NO bioavailability: Serum LOOH and plasma NO 2 increased in lowlanders following acute high-altitude exposure, by 17% (P=0.01) and 72% (P=0.06),
respectively (see Table 2 ). A significant negative correlation between LOOH and GTN-induced dilation was evident for initial arrival (n=11, r=-0.53; P=0.01) and chronic exposure (n=7, r=- Figure 4) ; however, once lowlanders were exposed to high altitude these between-group differences were not present (Table 1, Figure   4 ). Compared with lowlanders at sea level, highlanders systolic and diastolic CCA diameters were larger (11%; +0.7 ± 0.1 mm and +0.8 ± 0.2 mm, respectively; P≤0.005; Figure 3 ), and both FMD and GTN dilation displayed a trend of being reduced by 1.6 ± 3.0% (relative ~20%;
P<0.10) and 3.5 ± 4.7% (relative ~ 21%; P=0.07; Figure 5 ). However, again these between-group differences were absent when lowlanders were exposed to high altitude. In contrast, highlander's wall: lumen ratio was ~19% lower when compared to lowlanders at both sea level and at high altitude (P≤0.04; Figure 3 ).
Study 2 -Normobaric hypoxia and α 1 -adrenoreceptor blockade
Time course alterations to hypoxia within the placebo trial: Compared to normoxic baseline (0 min) SaO 2 was reduced and HR was elevated during hypoxic exposure (Table 3 ). Due to technical issues (i.e. loss of one recording), FMD time course related data within the placebo trial were obtained in 10 out of the 11 participants. Compared to normoxic baseline, FMD was reduced following 60 min, 210, and 330 min of hypoxia by 1.6 ± 0.2 % (relative 28%), 2.5 ± 0.1 % and 2.8 ± 0.2 % (relative 36%), respectively (P≤0.003; Figure 6 ). Although no significant difference was evident between normoxic conditions (baseline and 60-min post-hypoxia recovery), FMD was 1.3 ± 0.2 % (relative 16%) higher in normoxic recovery from hypoxia exposure.
The effect of the α 1 -adrenoreceptor blockade: Two-way repeated measures ANOVA (n=9) revealed a significant interaction between time and condition for HR and FMD. Pair t-test analysis revealed that compared to the placebo trial, HR and FMD were 5 ± 2 beats•min -1 (P=0.03; Table 3 ) and 1.8 ± 1.4 % (relative 35%; P=0.002; Figure 6 ) higher following α 1 -adrenoreceptor blockade after 330 min of hypoxic exposure.
Discussion
This is the first study to comprehensively examine the time course and potential mechanisms of alterations in vascular function and structure in healthy lowland individuals during normobaric hypoxia, upon ascent to and following a partial acclimatization to high altitude, and to provide relevant comparisons with high-altitude natives. Acute exposure to 5050 m in lowlanders was associated with an impairment in both endothelial-dependent (FMD) and endothelialindependent (GTN) dilatation, and an increase in central-PWV and CCA diameter. These changes were neither exacerbated nor resolved with chronic-high altitude exposure. Compared to lowlanders at sea level, highlanders had a lower FMD and GTN dilation response, a higher central-PWV and a larger CCA diameter. These between-group differences were removed when lowlanders were exposed to 5050 m, with only one exception (carotid wall: lumen ratio). In lowlanders, we found that alterations in elevations in oxidative stress were partially and selectively related to the reductions in GTN-induced vasodilation at 5050 m. In a follow-up placebo-controlled experiment conducted in a normobaric hypoxic chamber, we found that sustained reductions (-28-36%) in FMD occur within 60 min and could be partially reversed following α 1 -adrenoreceptor blockade. We conclude that high altitude exposure in lowlanders was associated with persistent impairment in vascular function, and was potentially mediated via oxidative stress and sympathoexcitation. Although a lifetime of high-altitude exposure does not intensify the observed vascular function impairments seen with acute exposure, chronic highaltitude exposure appears to be associated with altered arterial structure; whether this is an adaptive or maladaptive response remains to be established.
Influence of high altitude on vascular structure and function in lowlanders:
Flow mediated dilation, an index of cardiovascular risk (Mullen et al., 2001; Green et al., 2005; Green et al., 2012; Maruhashi et al., 2013) , was reduced by 14% in healthy lowlanders upon initial exposure to 5050 m, and did not change following ~2 weeks at this elevation. These findings contrast with those reported by Frick et al. (2006) , where FMD following 3 weeks at 1700 m was reduced by ~49%. However, given the methodological issues discussed above, comparison with this study is difficult. Given the comparable brachial baseline diameter and FMD shear stress between sea level and arrival to high altitude, the initial reduction in FMD with high altitude does not appear to be explained by alterations in diameter or the shear stress stimulus on the vessel. Moreover, our findings persisted following allometric scaling to control for variability in baseline diameter and therefore, improved specificity and interpretation of the FMD protocol (Atkinson & Batterham, 2013; Atkinson et al., 2013) .
We also quantified the peak vasodilatory capacity of the brachial artery, and found this too was reduced by 14% at high altitude. This measure is a valid index and surrogate measure for arterial structural remodelling (Naylor et al. 2005) . The artery dilation associated with the assessment of vasodilator capacity in the current study is less dependent on NO than the FMD assessment. For example, it has previously been shown that when cuff occlusion is proximal to the site of vascular imaging (as used in the current study for testing vasodilator capacity), NO accounts for only 40% of the dilation response (Doshi et al., 2001; Green et al., 2012) ; the degree of shear stress and release of multiple vasoactive substances contribute to the additional artery dilation (Green et al., 2012) . It would seem that a balance of NO and other vasoactive substances, in addition to neurogenic factors, underpin the vascular changes observed at high altitude, and are considered below.
Potential mechanisms of action for initial reduction in FMD:
A positive relationship between SaO 2 and FMD (r=0.62) has previously been reported, and 100% oxygen inhalation has been shown to improve FMD in hypoxemic (SaO 2 <90%), but not in normoxemic (SaO 2 <90%) control participants, suggesting that vascular dysfunction to high altitude, is partly influenced by hypoxemia (Rimoldi et al., 2012 ). In the current study, a similar weak-to-moderate relationship was evident between FMD and SaO 2 (r=0.33, P=0.05), and calculation of the coefficient of determination indicates that the change in SaO 2 potentially explained around 11% of the change in FMD; confirming the multifactorial nature of vascular dysfunction and that other mechanism(s) are involved in the impairment of FMD at high altitude.
In contrast to our hypothesis, and previous findings (Frick et al., 2006) , GTN-induced dilation in lowlanders was also reduced at both time points at high altitude. It is accepted that GTN-induced dilation provides an index of the maximum obtainable vasodilator response, and represents vascular smooth muscle function (Corretti et al., 2002; Maruhashi et al., 2013) . This particular assessment is used as a control test for FMD measures, as the assessment of FMD is based on the premise that endothelium-independent dilation is not altered, and any alterations seen in FMD measures is resultant of endothelial dysfunction, and not vascular smooth muscle dysfunction (Maruhashi et al., 2013) . Given that GTN-dilation and FMD were each reduced by ~14% with acute exposure to 5050 m, these findings indicate that alterations in vascular smooth muscle function and/or structure contributed to the decline in FMD at high altitude. The potential mechanism(s) by which ambient hypoxia alters vascular smooth muscle function/structure is unknown. Endothelial dysfunction associated with acute hypoxia at sea level, has been associated with a reduced NO-bioavailability in both humans (Cosby et al., 2003; Maher et al., 2008) and rodents (Reboul et al., 2005; Hernandez-Guerra et al., 2013) ; however, in agreement with others (Janocha et al., 2011; Beall et al., 2012) we found that vascular NO bioavailability (as indexed by plasma NO 2 ) increased with high altitude. Thus, it seems that vascular dysfunction clearly cannot be explained by reduced NO bioavailability per se, but is more likely related to additional factors including the direct vasculo-toxic/constrictive effects of elevations in LOOH, as confirmed by the observed correlation. Consistent with these findings, there is evidence to indicate that hypoxic upregulation of superoxide production (Dweik, 2005) potentially hinders the intravascular signalling processes in smooth muscle cells required for relaxation (e.g., soluble guanylyl cyclase and cGMP-dependent kinase; (Munzel et al., 2003; Maruhashi et al., 2013) . The elevations in NO at high altitude may well be an adaptive response to maintain circulatory homeostasis through both vasodilation and metabolic suppression [reviewed in: (Umbrello et al., 2013) ].
It is known that hypoxic-induced sympathoexcitation (Saito et al., 1988; Hansen & Sander, 2003) may potentially modulate functional, and/or mechanical properties of large arteries via an increase in vasomotor tone (Hijmering et al., 2002; Dyson et al., 2006; Fok et al., 2012) . To explore this possibility, we conducted a follow-up study in normobaric hypoxia to examine whether a similar reduction in FMD would occur in response to acute normobaric hypoxia, and the contributory role of increased sympathetic nerve activity via the α 1 -adrenoreceptor. Broadly consistent with our hypothesis, we found that FMD was markedly reduced in normobaric hypoxia (~28-35%). Moreover, following administration of the α 1 -blockade, these reductions in FMD were largely reversed back to normoxic baseline. Thus, our findings clearly support the notion that changes in FMD occur early within exposure to hypoxia and are under the influence of elevations in sympathetic nerve activity. We acknowledge that differences between normobaric and hypobaric hypoxia are possible, and the potential mechanism regulating the vascular response to shear stress may also differ.
Arterial stiffness: Lowlanders experienced an 11% increase in central-PWV with high altitude exposure, with no change in peripheral-PWV. Carotid to femoral PWV is considered the noninvasive gold standard measure of arterial stiffness (Laurent et al., 2006) , and is influenced by the tone of arterial smooth muscle irrespective of the signalling pathway in which it is modulated (Fok et al., 2012) . Vascular smooth muscle tone is affected by both endothelial cell signalling and the sympathetic nervous system (Wilkinson & McEniery, 2004; Bruno et al., 2012) . As highlighted above, the FMD and GTN findings in the current study support impairment in endothelial function and increase in smooth muscle tone, both of which alone or in combination may explain our observed increase in central-PWV.
It is important to note that the anatomy of arteries and the extent to which smooth muscle tone influences stiffness is not homogenous across the vascular tree, e.g., muscular arteries (radial) unlike elastic arteries (carotid) show little stiffening with ageing (Avolio et al., 1985; Stewart et al., 2003) . Additionally, structural changes can be present without obvious functional changes and vice versa (Naghavi, 2009) . The results of the current study support this concept. In support of arterial differences along the vascular tree with ambient hypoxia, our lowlander group experienced a ~7% increase in CCA diameter at 5050 m, whereas brachial diameter was unchanged. Although the regional mechanisms are unknown, the differential effects of hypoxia on vessel dilation would seem of physiological benefit in that dilation of the CCA would act to redistribute blood flow towards the cerebral vessels to help maintain a normal oxygen flux to the brain in the face of arterial hypoxemia (Ainslie & Ogoh, 2010) .
Comparisons between lowlanders and highlanders: When compared to lowlanders at sea level, et al., 2012) . It has been suggested that exercise training induces an increase in shear stress and transmural pressure (Tuttle et al., 2001; Laughlin et al., 2008; Green et al., 2011) ; these collective changes can increase the circumferential strain placed on the blood vessel and stimulate structural arterial remodelling and an anti-atherogenic effect, resulting specifically in luminal expansion (Laughlin et al., 2008; Rowley et al., 2012) . Although we do not provide evidence to support the above concept with high altitude exposure, the increase in carotid diameter in lowlanders with high altitude exposure may indicate that arterial remodelling is an adaptive response to high altitude.
Perspectives
The high-altitude induced changes in FMD/GTN dilation and central-PWV in lowlanders and the comparison with highlanders has potential clinical relevance. This is especially evidenced in native highlanders who have been reported to show earlier cardiovascular degeneration changes with aging, in particular arterial wall stiffening (Otsuka et al., 2005) . It has been estimated that a 1% (absolute) decrease in FMD is associated with a 9% increase in cardiovascular risk (Green et al., 2012) ; and a 1 m·s -1 increase in aortic stiffness (central-PWV) accounts for a 15% increase in cardiovascular and all-case mortality (Vlachopoulos et al., 2010) . The absolute mean differences in FMD and central-PWV between highlanders at high altitude and lowlanders at sea level were 1.6% and 1.0 m·s -1 , respectively; and the absolute change in lowlanders upon exposure to high altitude from sea level was 0.9% and 0.7 m·s -1 . These findings indicate that: 1) natives to high altitude are at greater risk of advanced vascular aging, due to impairment in endothelial and smooth muscle function; thus, lifelong adaption to high altitude does not appear to provide any functional cardioprotective benefits; and 2) the vascular alterations/adaptions in vascular endothelial and smooth muscle function with high-altitude exposure are significant enough to induce an increase in cardiovascular risk in healthy lowlanders. These findings may be particularly relevant to 'at-risk' populations who ascend to high altitude (e.g. patients with sleep apnoea, heart failure, lung disease, etc.). The potential risk and level of altitude required to induce adverse changes in vascular function remains to be established.
Methodological considerations
Due to the nature of high-altitude research, our sample size was relatively small. Nevertheless, clear significant differences were evident, indicating that additional numbers would be unlikely to alter our findings. An important consideration in the assessment of FMD in cross-sectional and longitudinal studies is that of consistency in the brachial baseline diameter and shear-stress stimulus and related normalisation (Atkinson et al., 2009; Green et al., 2012) . Following ~2 weeks at 5050 m, FMD was unaltered compared to initial arrival to high altitude. It is important to highlight that compared to initial exposure at 5050 m, the SR area under the curve stimulus influencing the FMD response was reduced by ~40% following the prolonged stay at 5050 m.
Despite this marked reduction in shear stress, the FMD reduction was markedly consistent across time at high altitude. Whether or not these changes in SR area under the curve reflect a subtle functional improvement in vascular function is unclear. In addition, the changes in FMD persisted following allometric scaling to control for variability in baseline diameter.
Although logistically difficult in field conditions or prolonged laboratory studies, complimentary measures of sympathetic nerve activity either via noradrenaline concentrations or muscle sympathetic nerve activity would have added to mechanistic interpretation to our findings. It is also known that physical fitness influences the brachial baseline diameter and hence FMD response (Green et al., 2013) . Although there were no significant differences in brachial baseline diameter between conditions (e.g., time at altitude) or groups (e.g., lowlanders vs. highlanders), Although we provided some insight into the role of oxidative stress and NO as potential mechanisms of vascular dysfunction, we were unable to collect these blood markers in the high altitude natives. As such, we do not know if similar changes and relationships may also be evident in this group. It is also important to acknowledge that evidence exists to indicate that highland groups with different evolutionary histories, e.g. Andean and Tibetan populations, differ from one another genetically, resulting in different adaptation responses to hypoxia (Beall, 2007; Bailey et al., 2013) . Therefore, as Tibetan highlanders were selected in the current study, caution is needed when comparing or interpreting the results of the current study with Andean populations. Further research is needed to explore vascular function in different highland groups. 
Conclusion
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Figure 2: Illustration of ultrasound images and analysis techniques for: A, brachial flow mediated dilation (custom-designed edge-detection and wall-tracking software was used to obtain simultaneous measure of diameter and flow). B, beat-to-beat common carotid diameter (custom-designed edge-detection and wall-tracking software was used to obtain beat-to-beat diameter). C, common carotid intima-media thickness (CIMT: commercial edge-detection software (EchoPAC PC, GE Healthcare) was used to measure CIMT across consecutive cardiac cycles). 
